002370 亚太药业
交易中 04-26 13:57:54
资讯
新帖
简况
亚太药业(002370.SZ)发2023年度业绩,净亏损1187.70万元,同比亏损收窄
智通财经网 · 03-29
亚太药业(002370.SZ)发2023年度业绩,净亏损1187.70万元,同比亏损收窄
亚太药业(002370.SZ)收到注射用阿昔洛韦一致性评价受理通知书
智通财经网 · 01-29
亚太药业(002370.SZ)收到注射用阿昔洛韦一致性评价受理通知书
加载更多
公司概况
公司名称:
浙江亚太药业股份有限公司
所属行业:
医药制造业
上市日期:
2010-03-16
主营业务:
浙江亚太药业股份有限公司主要从事医药制造业务,包括化学制剂、化学原料药的研发、生产和销售。公司主要产品包括抗阿莫西林克拉维酸钾分散片、阿奇霉素分散片、注射用阿奇霉素、罗红霉素胶囊、注射用头孢唑肟钠等。罗红霉素胶囊、头孢氨苄胶囊、阿奇霉素分散片及注射用阿奇霉素为本公司的主导产品。
发行价格:
16.00
{"stockData":{"symbol":"002370","market":"SZ","secType":"STK","nameCN":"亚太药业","latestPrice":3.13,"timestamp":1714111074000,"preClose":3.18,"halted":0,"volume":9893174,"delay":0,"floatShares":609000000,"shares":609000000,"eps":0.1789,"marketStatus":"交易中","marketStatusCode":2,"change":-0.05,"latestTime":"04-26 13:57:54","open":3.17,"high":3.17,"low":3.11,"amount":30945600,"amplitude":0.0189,"askPrice":3.13,"askSize":59,"bidPrice":3.12,"bidSize":9614,"shortable":0,"etf":0,"ttmEps":0.1789,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1714114800000},"adr":0,"adjPreClose":3.18,"symbolType":"stock","openAndCloseTimeList":[[1714095000000,1714102200000],[1714107600000,1714114800000]],"highLimit":3.5,"lowLimit":2.86,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":609179371,"pbRate":4.39,"roa":"--","roe":"--","epsLYR":-0.02,"committee":0.530533,"marketValue":1907000000,"floatMarketCap":1907000000,"peRate":17.495807,"changeRate":-0.0157,"turnoverRate":0.0162,"status":1},"requestUrl":"/m/hq/s/002370","defaultTab":"news","newsList":[{"id":"2423498832","title":"亚太药业(002370.SZ)发2023年度业绩,净亏损1187.70万元,同比亏损收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2423498832","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2423498832?lang=zh_cn&edition=full","pubTime":"2024-03-29 22:08","pubTimestamp":1711721280,"startTime":"0","endTime":"0","summary":"亚太药业发布2023年年度报告,报告期内公司实现营业收入4.21亿元,同比增长12.64%;归属于上市公司股东的净亏损1187.70万元,同比亏损收窄;归属于上市公司股东的扣除非经常性损益的净亏损6894.45万元;基本每股亏损0.02元/股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-29/doc-inapzekn1058041.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-29/doc-inapzekn1058041.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2407383664","title":"亚太药业(002370.SZ)收到注射用阿昔洛韦一致性评价受理通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2407383664","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2407383664?lang=zh_cn&edition=full","pubTime":"2024-01-29 16:01","pubTimestamp":1706515260,"startTime":"0","endTime":"0","summary":"亚太药业发布公告,公司于近日收到国家药品监督管理局下发的关于注射用阿昔洛韦一致性评价的受理通知书。公告称,注射用阿昔洛韦被国家药品监督管理局受理,标志着该品种一致性评价工作进入了审评阶段,公司将积极推进后续相关工作,如顺利通过一致性评价将增加其市场竞争力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-01-29/doc-inafeqqe3760682.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-01-29/doc-inafeqqe3760682.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2010-03-16","address":"浙江省绍兴市柯桥区群贤路2003号1501室","stockEarnings":[{"period":"1week","weight":0.0495},{"period":"1month","weight":-0.1215},{"period":"3month","weight":-0.1825},{"period":"6month","weight":-0.343},{"period":"1year","weight":-0.2464},{"period":"ytd","weight":-0.2587}],"companyName":"浙江亚太药业股份有限公司","boardCode":"AI0027","perCapita":"9500股","boardName":"医药制造业","registeredCapital":"60917万元","compareEarnings":[{"period":"1week","weight":-0.0069},{"period":"1month","weight":0.0071},{"period":"3month","weight":0.049},{"period":"6month","weight":0.0116},{"period":"1year","weight":-0.0647},{"period":"ytd","weight":0.0262}],"survey":" 浙江亚太药业股份有限公司主要从事医药制造业务,包括化学制剂、化学原料药的研发、生产和销售。公司主要产品包括抗阿莫西林克拉维酸钾分散片、阿奇霉素分散片、注射用阿奇霉素、罗红霉素胶囊、注射用头孢唑肟钠等。罗红霉素胶囊、头孢氨苄胶囊、阿奇霉素分散片及注射用阿奇霉素为本公司的主导产品。","serverTime":1714111076534,"listedPrice":16,"stockholders":"64119人(较上一季度减少5.51%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚太药业(002370)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚太药业(002370)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚太药业,002370,亚太药业股票,亚太药业股票老虎,亚太药业股票老虎国际,亚太药业行情,亚太药业股票行情,亚太药业股价,亚太药业股市,亚太药业股票价格,亚太药业股票交易,亚太药业股票购买,亚太药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚太药业(002370)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚太药业(002370)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}